|
Post by reality on Nov 3, 2016 19:48:20 GMT -5
|
|
|
Post by sportsrancho on Nov 3, 2016 19:59:55 GMT -5
|
|
|
Post by reality on Nov 3, 2016 20:10:08 GMT -5
Patients need to reach out to the offices of the lawmakers
|
|
|
Post by falconquest on Nov 3, 2016 20:32:59 GMT -5
Patients need to reach out to the offices of the lawmakers Mannkind needs to declare a price decrease even if gratuitous. Having been in sales for years the one thing I learned from a very knowledgeable veteran was, "You need to create a meaningful differential advantage" that differential advantage is in the face of insulin price increases Mannkind separates itself from the others by LOWERING their price. We already have "differential advantages" but those aren't recognized at this point. Shake up the market Mike and take advantage of the golden opportunity laid at your feet and announce a price decrease! Don't look a gift horse in the mouth, my god this is an opportunity staring you in the face! (can you tell I think this is obvious)!
|
|
|
Post by afrezzamiracle on Nov 3, 2016 20:54:12 GMT -5
Agree 100%. We are flat out desperate, in DIRE need of awareness. Take action management!
|
|
|
Post by afrezzamiracle on Nov 3, 2016 20:59:05 GMT -5
This strategy can gain us mindshare awareness and marketing exposure for free that money can't buy, and at a level that we simply unable to afford.
|
|
|
Post by mnkdnewbie on Nov 3, 2016 21:02:09 GMT -5
It will be interesting if they were all involved in price fixing. If they were I wonder if afrezza was ever mentioned in those conversations.
|
|
|
Post by surplusvalue on Nov 3, 2016 21:15:02 GMT -5
Patients need to reach out to the offices of the lawmakers Mannkind needs to declare a price decrease even if gratuitous. Having been in sales for years the one thing I learned from a very knowledgeable veteran was, "You need to create a meaningful differential advantage" that differential advantage is in the face of insulin price increases Mannkind separates itself from the others by LOWERING their price. We already have "differential advantages" but those aren't recognized at this point. Shake up the market Mike and take advantage of the golden opportunity laid at your feet and announce a price decrease! Don't look a gift horse in the mouth, my god this is an opportunity staring you in the face! (can you tell I think this is obvious)! Unfortunately it doesnt seem that management knows how to present the company to the market on many fronts(as I have mentioned many times before). When they had the golden opportunity to have Laura K. as a spokesperson on some medical/health shows at the same time as the focus on her in the magazine article they went only part way by advertising in the same magazine in close proximity to the article on her. They certainly had enough time to coordinate this. So here is another opportunity to differentiate itself and even more important make people aware of MNKD and Afrezza even if its only drawing attention to itself as not having its prices increase although as you say much more effective perhaps to draw attention by lowering it. I wouldnt hold my breath waiting though. Management has said that pricing is off the table.
|
|
|
Post by mnkdnewbie on Nov 3, 2016 21:26:05 GMT -5
It would be awesome if they subpoena any emails and there is proof of sand bagging afrezza in there. <======dreamer
|
|
|
Post by mnholdem on Nov 3, 2016 22:04:23 GMT -5
In retrospect, it's a good thing that MannKind's CCO Michael Castagna publicly stated that MannKind had not raised prices since Afrezza was introduced to the market. The License and Collaboration Agreement gave Sanofi 100% control of Afrezza prices.
It would have been much better, IMHO, if the CCO had announced a price reduction after getting the NDA returned to MannKind. Even if it were only a 1% price reduction, MannKind could have garnered some attention (and free press) for Afrezza.
It's water under the bridge now, but I think that MannKind passing the opportunity to have announced a price break was a tactical error.
|
|
|
Post by reality on Nov 3, 2016 22:36:25 GMT -5
In retrospect, it's a good thing that MannKind's CCO Michael Castagna publicly stated that MannKind had not raised prices since Afrezza was introduced to the market. The License and Collaboration Agreement gave Sanofi 100% control of Afrezza prices. It would have been much better, IMHO, if the CCO had announced a price reduction after getting the NDA returned to MannKind. Even if it were only a 1% price reduction, MannKind could have garnered some attention (and free press) for Afrezza. It's water under the bridge now, but I think that MannKind passing the opportunity to have announced a price break was a tactical error. I don't know if this opportunity is yet lost. They have another chance right now. Announce a small price decrease, let it be known to the press and you get a whole lot of attention. Reach out to the lawmakers, let them know that here is a small company bucking the trend. "NOT ONLY have we NOT raised the price, out of respect for our patients and because our founder said "take care of our patients first", we at Mannkind have decided to lower our pricing, by 5% EVEN though it costs us MORE to manufacture a powdered, MORE convenient, MORE DISCRETE, ULTRA FAST ACTING version of INSULIN that is indeed FDA approved. We BELIEVE that most insurance companies would be interested in saving their patients these costs and invite them to see for themselves what our patients are saying everyday." Mannkind Management -Are you listening?
|
|
|
Post by reality on Nov 3, 2016 22:40:32 GMT -5
The tactical error is saying "we haven't raised our prices" That is NOT what the press wants to hear. A negative negative---> They should say "We have lower pricing than the big pharma"
|
|
|
Post by mango on Nov 4, 2016 1:50:28 GMT -5
Oh. Mann. This. Could. Be. EPIC.
Someone needs to email Jason Chaffetz ASAP.
Oh wait, doesn't Kent Kresa know the POTUS? I think he knows a lot of people in high places. DARPA and the Carlyle Group. What's it gonna take to pick up the phone?
|
|
|
Post by mango on Nov 4, 2016 2:09:06 GMT -5
This is what comes to my mind when I see Eli Lilly making the headlines again for something illegal:
Eli Lilly was involved in one of the largest qui tam cases in history and Eli Lilly paid the largest individual corporation criminal fine EVER in a U.S. criminal prosecution of any kind! And, cannot forget: Scott W. Rothstein.
|
|
|
Post by mango on Nov 4, 2016 5:54:02 GMT -5
|
|